NEW YORK ( TheStreet) -- CHANGE IN RATINGS Automatic Data ( ADP) upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $68 price target. Company has superior cyclical earnings power. Beneficial Mutual Bancorp ( BNCL) upgraded to buy at TheStreet Ratings. Brocade ( BRCD) rated new Neutral at Sterne Agee. Valuation call, as the company is still in the early stages of a growth turnaround. Buffalo Wild Wings ( BWLD) upgraded at Wedbush from Neutral to Outperform, Wedbush said. $100 price target. Menu prices are higher but wing costs have remained stable. Capitol Federal ( CFFN) downgraded at KBW to Market Perform, Keefe, Bruyette & Woods said. $12.50 price target. Company should see muted near-term earnings growth. Central Pacific Financial ( CPF) upgraded to hold at TheStreet Ratings. Dollar Tree ( DLTR) upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. New analyst has a $55 price target. Family Dollar ( FDO) upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $81 price target. New analyst believes that the new management team can improve the company's earnings power. Fidelity National ( FIS) upgraded at Baird from Neutral to Outperform, Robert Baird said. $38 price target. Valuation call, as the stock has pulled back 17% since July. Gardner Denver ( GDI) downgraded at Keybanc from Buy to Hold, Keybanc said. Estimates also cut, given lower demand for drilling pumps. Hewlett-Packard ( HPQ) downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. Company faces both secular and structural headwinds. Informatica ( INFA) upgraded at Baird to Buy, Robert Baird said. $33 price target. Stock is attractive to buy, following a 23% selloff. Marriott ( MAR) downgraded at Lazard from Buy to Neutral, Lazard said. Estimates also cut, as the company is realizing lower RevPAR growth. Marriot downgraded at UBS to Neutral from Buy, UBS said. $42 price target. Valuation call, remain positive on lodging recovery. MarketAxess ( MKTX) rated new Market Perform at BMO. $33 price target. Stock is already pricing in strong expected growth. MeadWestvaco ( MWV) downgraded at Goldman to Neutral, Goldman Sachs said. Company is leveraged to lower bleached board prices. $30 price target. Owens-Illinois ( OI) upgraded at Goldman to Buy, Goldman Sachs said. $28 price target. New CFO is improving the company's capital allocation strategy.
Rockwood ( ROC) rated new Buy at BofA/Merrill. $58 price target. Company can see earnings growth accelerate in 2014. Skyworks ( SWKS) rated new Buy at Lazard. $30 price target. Stock can recover and the company emerges as the clear winner from the iPhone 5. Thermo Fisher ( TMO) upgraded at Wells to Outperform from Market Perform, Wells Fargo said. Company is leveraged to a strong mass spectrometer market. Vanguard Natural ( VNR) rated new Buy at UBS. $33 price target. Growing steadily and paying monthly. Zynga ( ZNGA) downgraded at Baird to Neutral, Robert Baird said. $3 price target. Company cut its guidance again. Zynga downgraded at BofA/Merrill from Neutral to Underperform, Bank of America/Merrill Lynch said. $2.70 price target. Estimates also cut, given the company's new guidance.
Twitter and become a fan on Facebook.
STOCK COMMENTS / EPS CHANGESAlexion Pharmaceuticals ( ALXN) numbers raised at Oppenheimer. Shares of ALXN now seen reaching $134, Oppenheimer said. Estimates also raised on headroom in the orphan disease franchise. Outperform rating. Endo ( ENDP) numbers cut at UBS. Shares of ENDP now seen reaching $45, UBS said. Estimates also lowered following investor day. Buy rating. Facebook ( FB) estimates, target reduced at JP Morgan. Shares of FB now seen reaching $28, according to JP Morgan. Estimates also cut, given the company's exposure to ZNGA. Overweight rating. Gap ( GPS) estimates, target increased at Piper. GPS estimates were raised through 2014, Piper Jaffray said. Company is carrying sales momentum into the Fall season. Overweight rating and new $42 price target. Informatica ( INFA) numbers cut at JMP. INFA estimates were reduced through 2013, JMP Securities said. Company cut guidance for a second straight quarter. Outperform rating and new $38 price target. Impax Labs ( IPXL) numbers boosted at BofA/Merrill. Shares of IPXL now seen reaching $25, according to Bank of America/Merrill Lynch said. Estimates also upped, as the company is seeing higher generic sales. Underperform rating. Marriott ( MAR) estimates, target raised at Nomura. Shares of MAR now seen reaching $48, according to Nomura. Estimates also increased, given higher expected RevPAR growth. Buy rating. >To submit a news tip, email: firstname.lastname@example.org.
READERS ALSO LIKE:
Twitter and become a fan on Facebook.